Publicaciones en colaboración con investigadores/as de Netherlands Cancer Institute (58)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  2. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  3. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  4. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer: (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA)

    European Journal of Nuclear Medicine and Molecular Imaging

  5. Joint EANM-SNMMI guidelines on the role of 2-[18F]FDG PET/CT in no special type breast cancer: differences and agreements with European and American guidelines

    European Journal of Nuclear Medicine and Molecular Imaging

  6. Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors

    Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641

  7. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. Detailed dosimetric evaluation of inter-fraction and respiratory motion in lung stereotactic body radiation therapy based on daily 4D cone beam CT images

    Physics in Medicine and Biology, Vol. 68, Núm. 1

  4. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  5. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine

  6. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  7. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  8. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

  9. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

    Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60

  10. Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617

  11. Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Obstetrical and Gynecological Survey

  12. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61

  13. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533